FIG. 2



CPM
140000
120000
100000
80000
60000
40000
20000
0
0
3
33
100
µg/ml of each peptide

FIG. 1



Average CPM
140000
120000
100000
80000
60000
40000
20000
0
0
0.5
5
50
µg/ml of each peptide

FIG. 4



Mean Specific Lysis
55
45
35
25
15
5
-5
Class I-restricted peptide + Control Ig
Class I-restricted peptide + B7.2Ig
Class I + Class II-restricted peptides + Control Ig
Class I + Class II-restricted peptides + B7.2Ig
Live virus

FIG. 3



Mean Specific Lysis
70
60
50
40
30
20
10
0
Class I-restricted peptide alone
Class I-restricted peptide + B7.2Ig
B7.2Ig alone
Live virus

FIG. 5A




FIG. 5B




FIG. 5C




FIG. 6



non-immunized
irradiated tumor cells
irradiated tumor cells + B7.1-IgG
irradiated tumor cells + B7.2-IgG
irradiated tumor cells + mutated B7.1-IgGmut
irradiated tumor cells + mutated B7.2-IgGmut
B7.1-IgG alone
B7.2-IgG alone
0%
10%
20%
30%
40%
50%
60%
70%
80%
% protected against live-tumor challenge

FIG. 7A




FIG. 7B




FIG. 7C




FIG. 7D




FIG. 7E




FIG. 7F




FIG. 7G




FIG. 7H




FIG. 8A




FIG. 8B




FIG. 8C




FIG. 8D




FIG. 8E




FIG. 8F




FIG. 8G





FIG. 8H





non-immunized control
irradiated P815
irradiated P815 + B7.1-IgG
irradiated P815 + B7.2-IgG
B7.1-IgG alone
B7.2-IgG alone
P815 tumor model
mean tumor size in mm x mm
days after tumor inoculation
0
100
200
300
400
0
10
20
30
40
50
60
70

FIG. 9A



non-immunized control
irrad. MethA
irrad. MethA + B7.1-IgG
irrad. MethA + B7.2-IgG
B7.1-IgG alone
B7.2-IgG alone
MethA tumor model
mean tumor size in mm x mm
days after tumor inoculation
0
20
40
60
80
100
0
5
10
15
20
25

FIG. 9B



MB49 tumor model
mean tumor size in mm x mm
days after tumor innoculation
PBS treated control
irrad. MB49
irrad. MB49 + B7.1-IgG
irrad. MB49 + B7.2-IgG
B7.1-IgG alone
B7.2-IgG alone
0
20
40
60
80
100
120
0
5
10
15
20
25

FIG. 9C



B16/F10 tumor model
mean tumor size in mm x mm
days after tumor innoculation
non immunized control
irradiated B16/F10
irradiated B16 + B7.1-IgG
irradiated B16 + B7.2-IgG
B7.1-IgG alone
B7.2-IgG alone
0
50
100
150
200
250
300
350
400
5
15
25
35
45
55

FIG. 9D




FIG. 10A




FIG. 10B




FIG. 10C




FIG. 10D

FIG. 11A

CD8 depleted untreated




FIG. 11B

CD8 depleted therapy with 50 μg B7.2-IgG




FIG. 11C

CD4 depleted untreated




FIG. 11D




FIG. 11E




FIG. 12A




FIG. 12B




FIG. 12C




FIG. 12D




FIG. 12E




FIG. 12F

